RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...
2488 Grand Concourse, suite 314, Bronx NY 10458
+1786-550-1661
info@holdingsolutioninc.com
Copyright © 2023 holdingsolutioninc. All Rights Reserved